Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for BiondVax Pharmaceuticals Ltd. (BVXV : NSDQ)
 
 • Company Description   
BiondVax Pharmaceuticals Ltd. is a biopharmaceutical company. The company's product includes Multimeric-001 universal flu vaccine which provides multi-season and multi-strain protection against human influenza virus strains. BiondVax Pharmaceuticals Ltd. is based in Ness Ziona, Israel.

Number of Employees: 15

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.30 Daily Weekly Monthly
20 Day Moving Average: 86,280 shares
Shares Outstanding: 11.35 (millions)
Market Capitalization: $14.76 (millions)
Beta: 2.52
52 Week High: $4.19
52 Week Low: $1.00
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -3.70% 8.45%
12 Week 5.69% 16.18%
Year To Date -44.68% -32.93%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
JERUSALEM BIOPARK 2ND FLOOR HADASSAH EIN KEREM CAMPUS
-
JERUSALEM,L3 00000
ISR
ph: 972-8930-2529
fax: 972-8930-2531
j.phillipson@biondvax.com http://www.biondvax.com
 
 • General Corporate Information   
Officers
Amir Reichman - Chief Executive Officer and Director
Mark Germain - Chairman
Elad Mark - Chief Operating Officer
Uri Ben-Or - Chief Financial Officer
Jay Green - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 09073Q105
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 12/01/21
Next Expected EPS Date: 06/22/22
Share - Related Items
Shares Outstanding: 11.35
Most Recent Split Date: (:1)
Beta: 2.52
Market Capitalization: $14.76 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $0.00 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.41 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 06/22/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.97
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 100.00%
vs. Previous Quarter: 100.00%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -
12/31/21 - -274.80
09/30/21 - -808.45
ROA
03/31/22 - -
12/31/21 - -45.25
09/30/21 - -53.41
Current Ratio
03/31/22 - -
12/31/21 - 7.64
09/30/21 - 0.51
Quick Ratio
03/31/22 - -
12/31/21 - 7.64
09/30/21 - 0.51
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - -
12/31/21 - 0.66
09/30/21 - 0.11
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - -
12/31/21 - 2.71
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - -
12/31/21 - 73.05
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©